UK health committee to investigate pharma regulation after Brexit
27-09-2017
The House of Lords is hearing from companies and regulators today on issues including the government’s life sciences strategy and Brexit’s impact on the industry.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
House of Lords; life sciences; Brexit; life sciences strategy; life sciences investment; Professor Sir John Bell
